Global Newswire by Notified: M&A

APRIL 29, 2024

The acquisition of Camlab bolsters Calibre Scientific’s growing product and service portfolio across the United Kingdom. The acquisition of Camlab bolsters Calibre Scientific’s growing product and service portfolio across the United Kingdom.

Pharmaceutical 45

Pharmaceutical Food Portfolio Acquisitions 45

OfficeHours

JANUARY 26, 2024

Buyout houses from Thoma Bravo to Permira are putting portfolio company sales high on the agenda for early 2024, as the industry seeks to return money to investors after a challenging period for exiting holdings. Some dealmakers claim the impact of elections on mergers and acquisitions is minimal. First, they want to earn.

Private Equity 130

Private Equity Equities Mergers and Acquisitions Investors 130

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion; and Roche’s acquisition of Carmot Therapeutics for up to $3.1

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Software Equity Group

AUGUST 20, 2024

One strategy gaining momentum is the acquisition of high-growth SaaS companies. This opens the door to significant investment and acquisition opportunities for SaaS companies from strategic buyers within and outside of the software industry. The company made 15 acquisitions in 2023. But value extends far beyond market access.

Investment 52

Investment Management Acquisitions Business 52

Software Equity Group

JUNE 6, 2023

 Ideagen is a leading provider of software solutions to regulated and high-compliance industries, including pharmaceutical, aerospace and defense, and life sciences. The Tritan-Ideagen deal demonstrates the value of strategic acquisitions as a method for entering new markets and expanding globally.

M&A 52

M&A Mergers and Acquisitions Middle Market Acquisitions 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Mergers and Inquisitions

NOVEMBER 1, 2023

They do not invest in risky biotech startups attempting to cure cancer (at least not within their traditional PE portfolios). PE firms view these companies as especially appealing since low multiples mean they can use higher debt percentages to fund the acquisitions. to consolidate their market power in specific regions. in biology.

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Devensoft

AUGUST 22, 2023

Understanding Freelance Modeling in M&A In the realm of mergers and acquisitions (M&A), freelance modeling emerges as a dynamic and adaptive methodology, offering a departure from traditional approaches. Consider a merger between a pharmaceutical company and a biotech startup.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Cooley M&A

JANUARY 22, 2021

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion.

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 approved prescription cannabidiol medicine to its portfolio. With COVID?19

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Devensoft

AUGUST 24, 2023

By melding the proficiencies, assets, and potentials residing within distinct business sectors or entities under a single organizational umbrella, the practice of mergers and acquisitions unveils dormant possibilities, propels inventive evolution, and champions the delivery of unparalleled outcomes.

Business 52

Business Collaboration Mergers and Acquisitions Management 52

Cooley M&A

FEBRUARY 15, 2017

We are seeing funds increasingly fundraising for tech plays and are acquiring the needed sector expertise to build their tech portfolios. The continued publicity and political focus on drug pricing has created uncertainty in valuing specialty pharmaceutical and biotech companies.

M&A 40

M&A IPO Pharmaceutical Valuation 40

InvestmentBank.com

MAY 18, 2021

The healthcare industry is formed of numerous subsectors including pharmaceutical services, diagnostics, medical technologies, and managed healthcare. Payor services and pharmaceutical services have generated the most return throughout 2016 and in 1Q 2017. The pharmaceutical industry is valued highly given the performance of buyouts.

Healthcare 40

Healthcare M&A Valuation Hospitality 40